Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.41 |
| ▸ | TYK2 | P29597 | 9/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948003 | 1.00 | ELANE (0.41) | ELANEIRAK4TYK2RXFP1 | |
| SCHEMBL20697198 | 1.00 | ELANE (0.41) | ELANEIRAK4TYK2RXFP1 | |
| SCHEMBL21238747 | 1.00 | ELANE (0.41) | ELANEIRAK4TYK2RXFP1 | |
| SCHEMBL25793921 | 1.00 | ELANE (0.41) | ELANEIRAK4TYK2RXFP1 | |
| SCHEMBL21227578 | 1.00 | ELANE (0.41) | ELANEIRAK4TYK2RXFP1 | |
| SCHEMBL24573835 | 0.90 | ELANE (0.42) | ELANEIRAK4RXFP1 | |
| SCHEMBL21258549 | 0.87 | TYK2 (0.45) | ELANETYK2 | |
| SCHEMBL20689313 | 0.87 | TYK2 (0.45) | ELANETYK2 | |
| SCHEMBL21238827 | 0.87 | TYK2 (0.45) | ELANETYK2 | |
| SCHEMBL21238674 | 0.87 | TYK2 (0.45) | ELANETYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2025-08-28 | — | — | US | disclosed |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267566-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116940572-A | 2H-indazole derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022140415-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140415-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140425-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140425-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268877-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | ELANE 4741/4885IRAK4 1/4885TYK2 15/4885 |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK1, IRAK2 | ELANE 4818/4885IRAK4 1/4885TYK2 19/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ELANE 4836/4885IRAK4 30/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.